Dr. Maricich brings a unique blend of medical practice, drug development, and digital health experience and expertise.  

 

He is a licensed, board-certified physician-scientist, investor, clinical/therapeutic developer and strategist. He improves our healthcare system by investing in, advising for, & leading innovative firms.  He has practiced clinically, caring for patients, as well as lead successful teams+programs at healthcare & biotech (HLS) firms including Xdynia (acquired by Cavion), Cavion (acq by Jazz Pharmaceuticals), Corixa (acq by GlaxoSmithKline), Pear Therapeutics (Nasdaq: $Pear), (1st FDA-market authorized, clinically-validated digital therapeutic to treat disease + reSET-O 1st for combo with pharmacotherapy, Somryst for chronic insomnia), and its end-to-end platform including decentralized virtual studies . He founded a digital health firm as med student that structured clinical data using NLP.  

​

He has worked across, biotech (small-molecules, AI-drug discovery across multiple disease areas), therapeutics & investment firms, including therapeutics, digital health, AI/analytics/cloud, delivery, medical device, and IP law.  Dr. Maricich was in Michael Porter’s first Value-Driven Health Care course at Harvard.  As a medical student he founded the Pathos Project. He is a published author & frequent speaker. 

 

Dr. Maricich has significant experience developing therapeutics and products across the entire life-cycle from pre-clinical, IND, clinical development, FDA approval/authorization, and post-market studies.  Rapidly building longitudinal evidence across clinical trials (RCTs), real-world evidence (RWE), and Health Economic Outcomes (HEOR/HCRU) is an area of expertise.  He has been instrumental in securing payor coverage, reimbursement, as well as obtaining multiple codes (NDC, HCPC, and CPT).  

​

Dr. Maricich completed his education and training at Harvard University, the University of Washington, the University of Notre Dame, and the University of Virginia.